Partnering
Better Together
Partnering with Fortvita Biologics
Fortvita Biologics seeks strategic partnerships to accelerate the development and global accessibility of breakthrough therapies for patients worldwide. Building on our strong foundation in oncology and expanding therapeutic areas, we collaborate with biopharma and biotech companies with the aim of addressing critical unmet medical needs across multiple disease areas.
Our Partnership Approach
Global Development Collaborations
We partner with leading pharmaceutical and biotech companies to advance our pipeline assets through clinical development. These collaborations leverage our partners’ global infrastructure alongside Fortvita’s innovative investigational therapies to efficiently explore potential treatments.
Research & Discovery Alliances
Our scientific expertise in novel bispecific antibodies and antibody-drug conjugates (ADCs) provides a strong foundation for early-stage research collaborations. We welcome partnerships to explore new therapeutic targets, combination strategies, and innovative treatment modalities.
Access & Distribution Partnerships
We seek partners with established distribution networks and market expertise in regions worldwide as we work toward fulfilling our mission of expanding global access to life-changing therapies beyond traditional markets.
Why Partner with Fortvita?
Advanced Pipeline & Regulatory Momentum
Our pipeline includes promising clinical-stage assets with demonstrated efficacy, including FT363 (PD-1/IL-2α bispecific), FT343 (CLDN18.2 ADC), and FT3009 (DLL3-targeted ADC). These programs have received important regulatory designations, including Breakthrough Therapy Designation and Fast Track Designation, potentially accelerating development timelines.
Global Perspective & Expertise
With our foundation in Innovent’s success and expanded global mission, Fortvita brings unique perspective on developing therapies across diverse markets. Our team brings deep experience in oncology drug development with specialized knowledge in bispecific antibodies, ADCs, and immunotherapies.
Flexible Partnership Models
We offer customized collaboration structures tailored to each partner’s needs and program objectives, from full global development and commercialization partnerships to regional licensing agreements and targeted research collaborations.
Let’s Work Together
Partnership Opportunities
Global and regional development and commercialization partnerships for our clinical-stage oncology assets
Research collaborations exploring novel combination strategies for our immunotherapy platforms
Manufacturing and supply chain partnerships to support global accessibility initiatives
Academic and research institution collaborations to explore new therapeutic applications
